The product development pipeline is shown below:
In addition to SCENESSE®, CLINUVEL’s pipeline includes:
- PRÉNUMBRA® Instant, a liquid formulation of afamelanotide which offers flexibility to personalise treatment and achieve an effective clinical response. PRÉNUMBRA® has been first used in the second clinical study in stroke (refer below), which started in March 2023. PRÉNUMBRA® Modified release is also under development.
- Instant and Modified release formulations of adrenocorticotropic hormone (ACTH) under the brand name NEURACTHEL®, with plans to develop these products for the treatment of neurological, endocrinological, and degenerative disorders. CLINUVEL plans to apply NEURACTHEL® in the first instance to the treatment of adult Multiple Sclerosis and Infantile Spasms.